Tarah J. Ballinger

2.0k total citations
49 papers, 727 citations indexed

About

Tarah J. Ballinger is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tarah J. Ballinger has authored 49 papers receiving a total of 727 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 15 papers in Cancer Research and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tarah J. Ballinger's work include HER2/EGFR in Cancer Research (10 papers), Cancer Risks and Factors (9 papers) and Advanced Breast Cancer Therapies (9 papers). Tarah J. Ballinger is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Cancer Risks and Factors (9 papers) and Advanced Breast Cancer Therapies (9 papers). Tarah J. Ballinger collaborates with scholars based in United States, Canada and Saudi Arabia. Tarah J. Ballinger's co-authors include Vandana G. Abramson, Jennifer A. Pietenpol, Brian D. Lehmann, Valerie M. Jansen, Kathy D. Miller, Melinda E. Sanders, Sandra K. Althouse, Bryan P. Schneider, Anna Maria Storniolo and Barbara L. Andersen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Tarah J. Ballinger

48 papers receiving 717 citations

Peers

Countries citing papers authored by Tarah J. Ballinger

Since Specialization

Citations

This map shows the geographic impact of Tarah J. Ballinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tarah J. Ballinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tarah J. Ballinger more than expected).

Fields of papers citing papers by Tarah J. Ballinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tarah J. Ballinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tarah J. Ballinger. The network helps show where Tarah J. Ballinger may publish in the future.

Co-authorship network of co-authors of Tarah J. Ballinger

This figure shows the co-authorship network connecting the top 25 collaborators of Tarah J. Ballinger. A scholar is included among the top collaborators of Tarah J. Ballinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tarah J. Ballinger. Tarah J. Ballinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidence 2025 ·JNCI Cancer Spectrum ·Jennifer W. Bea, Heather M. Ochs‐Balcom, (unknown), Zhao Chen, Robert M. Blew, Kimberly E. Lind, Bette J. Caan, Denise J. Roe, Thomas E. Rohan, Katherine W. Reeves, JoAnn E. Manson, Tarah J. Ballinger, Kerryn W. Reding, (unknown), (unknown), Andrew Odegaard	2
2	Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer 2024 ·Scientific Reports ·Tara Seibert, Lei Shi, Sandra K. Althouse, Richard L. Hoffman, Bryan P. Schneider, (unknown), (unknown), Stuart J. Warden, Theresa A. Guise, Andrew R. Coggan, Tarah J. Ballinger	1
3	Social Support, Social Strain, Stressful Life Events and Mortality Among Postmenopausal Women With Breast Cancer 2024 ·Psycho-Oncology ·(unknown), Michael S. Simon, Candyce H. Kroenke, Jessica L. Krok‐Schoen, Su Yon Jung, Rowan T. Chlebowski, Tarah J. Ballinger, Margaret S. Pichardo, Mace Coday, Lorena García, Juhua Luo	1
4	ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer. 2024 ·Journal of Clinical Oncology ·Tarah J. Ballinger, Fengmin Zhao, Joseph A. Sparano, Sofia F. Garcia, Fei Shen, Shamsuddin Virani, (unknown), Erica Stringer-Reasor, (unknown), (unknown), Della Makower, (unknown), Melissa A. Simon, Edith P. Mitchell, Angela DeMichele, Kathy D. Miller, Lynne I. Wagner, Antonio C. Wolff, Bryan P. Schneider	1
5	Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer 2024 ·npj Breast Cancer ·Tarah J. Ballinger, Mary Lou Smith, (unknown), Gregory D. Zimet, Bryan P. Schneider	1
6	Exercise as part of survivorship care in metastatic breast cancer: protocol for the randomized EMBody trial 2024 ·BMC Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Pengyue Zhang, Nada Kassem, Navin Kaushal, (unknown), (unknown), Jennifer A. Ligibel, Tarah J. Ballinger	1
7	Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer 2023 ·JAMA Oncology ·Brian D. Lehmann, Vandana G. Abramson, Elizabeth Claire Dees, Payal D. Shah, Tarah J. Ballinger, Claudine Isaacs, Cesar A. Santa‐Maria, Hanbing An, Paula I. González-Ericsson, Melinda E. Sanders, (unknown), Richard G. Abramson, Quanhu Sheng, Chih–Yuan Hsu, Yu Shyr, Antonio C. Wolff, Jennifer A. Pietenpol	18
8	NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer 2023 ·Cancer Discovery ·Brandie C. Taylor, Xiaopeng Sun, Paula I. González-Ericsson, Violeta Sánchez, Melinda E. Sanders, (unknown), Susan R. Opalenik, Ann Hanna, (unknown), Luc Van Kaer, Henry Gómez, Claudine Isaacs, Tarah J. Ballinger, Cesar A. Santa‐Maria, Payal D. Shah, Elizabeth Claire Dees, Brian D. Lehmann, Vandana G. Abramson, Jennifer A. Pietenpol, Justin M. Balko	31
9	Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112 2023 ·Journal of the National Comprehensive Cancer Network ·Tarah J. Ballinger, Helga S. Marques, (unknown), Richard L. Hoffman, Constantine Gatsonis, Fengmin Zhao, Kathy D. Miller, Joseph A. Sparano, Roisín M. Connolly	4
10	Racial Disparities in Cascade Testing for Cancer Predisposition Genes 2023 ·SSRN Electronic Journal ·Nawal Kassem, Sandra K. Althouse, Patrick O. Monahan, Lisa Hayes, Sarah M. Nielsen, Brandie Heald, Edward D. Esplin, Kathryn E. Hatchell, Tarah J. Ballinger	1
11	Racial disparities in cascade testing for cancer predisposition genes 2023 ·Preventive Medicine ·(unknown), Sandra K. Althouse, Patrick O. Monahan, Lisa Hayes, Sarah M. Nielsen, Brandie Heald, Edward D. Esplin, Kathryn E. Hatchell, Tarah J. Ballinger	9
12	Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer 2022 ·Clinical Cancer Research ·Milan Radovich, Jeffrey P. Solzak, (unknown), Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria Storniolo, Tarah J. Ballinger, Bryan P. Schneider, Kathy D. Miller	21
13	Exercise load monitoring: integrated approaches to advance the individualisation of exercise oncology 2021 ·BMJ Open Sport & Exercise Medicine ·Stephen J. Carter, Marissa N. Baranauskas, Tarah J. Ballinger, Laura Q. Rogers, Kathy D. Miller, Dustin Nabhan	3
14	Physical activity and risk of benign proliferative epithelial disorders of the breast, in the Women’s Health Initiative 2021 ·International Journal of Epidemiology ·Rita Peila, Rowan T. Chlebowski, Tarah J. Ballinger, Victor Kamensky, Phyllis A. Richey, Nazmus Saquib, Aladdin H. Shadyab, Sylvia Wassertheil‐Smoller, Thomas E. Rohan	2
15	Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer 2020 ·Contemporary Clinical Trials ·Catherine E. Mosher, (unknown), Adam T. Hirsh, Kathy D. Miller, Tarah J. Ballinger, Anna Maria Storniolo, Bryan P. Schneider, (unknown), Victoria L. Champion, Shelley A. Johns	3
16	Patient‐reported outcomes in the Translational Breast Cancer Research Consortium 2019 ·Cancer ·Deborah J. Bowen, Eileen H. Shinn, (unknown), Gretchen Kimmick, Laura S. Dominici, Elizabeth S. Frank, Karen L. Smith, Gabrielle B. Rocque, Kathryn J. Ruddy, (unknown), Michelle Melisko, Tarah J. Ballinger, Oluwadamilola M. Fayanju, Antonio C. Wolff	5
17	Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer 2018 ·PMC ·Tarah J. Ballinger, (unknown), Valerie M. Jansen	4
18	Impact of primary breast cancer therapy on energetic capacity and body composition 2018 ·Breast Cancer Research and Treatment ·Tarah J. Ballinger, (unknown), Sandra K. Althouse, (unknown), Kathy D. Miller, (unknown)	12
19	Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer 2018 ·Frontiers in Oncology ·Tarah J. Ballinger, (unknown), Valerie M. Jansen	61
20	Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling 2014 ·Breast Cancer Research and Treatment ·Vandana G. Abramson, (unknown), Tarah J. Ballinger, Melinda E. Sanders, Liping Du, (unknown), Zengliu Su, Ingrid A. Mayer, Mia Levy, (unknown), Cindy L. Vnencak‐Jones, Yu Shyr, Kimberly B. Dahlman, William Pao, Carlos L. Arteaga	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact